List view / Grid view
15 September 2015 | By Victoria White
Not only are Saxenda 'early responders' more likely to achieve greater weight loss, they are also more likely to experience greater improvements in cardiometabolic risk factors...
15 September 2015 | By Victoria White
Crucell Holland has been awarded $28.5 million from BARDA to help accelerate the development of its investigational Ebola prime-boost vaccine regimen...
15 September 2015 | By Victoria White
The agreement is in line with the Daiichi Sankyo R&D strategy to expand its portfolio in the prevention and treatment of thrombosis...
14 September 2015 | By Victoria White
The Phase 3 programme includes two replicate three-month efficacy studies and a single 12-month safety study...
14 September 2015 | By Victoria White
A supplemental New Drug Application (sNDA) for Imbruvica (ibrutinib) has been submitted to the US Food and Drug Administration (FDA) for front-line use in patients with chronic lymphocytic leukaemia (CLL).
14 September 2015 | By Victoria White
Under the terms of the offer, Perrigo shareholders will receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share...
14 September 2015 | By Victoria White
Patients who were treated with increasing doses of resveratrol over 12 months showed little or no change in amyloid-beta40 (Abeta40) levels...
14 September 2015 | By Victoria White
A clinical study demonstratement that ustekinumab can improve psoriasis symptoms and lessen its impact on quality of life in young people aged 12 and over...
14 September 2015 | By Victoria White
The fixed-ratio combination of insulin glargine and lixisenatide, a GLP-1 receptor agonist, demonstrated statistically superior reduction in HbA1c compared with insulin glargine alone...
The US Food and Drug Administration (FDA) has approved AbbVie’s Humira (adalimumab) for the treatment of moderate to severe hidradenitis suppurativa.
11 September 2015 | By Victoria White
Allergan has said that its partner, Perrigo, will begin shipments of the products to its retail and wholesale customers in the US in time for the 2016 cough and cold season...
11 September 2015 | By Victoria White
Biogen is assessing the potential of MT-1303 in multiple sclerosis (MS), ulcerative colitis, Crohn’s disease, and other autoimmune indications...
11 September 2015 | By Victoria White
The facility will eventually double AstraZeneca’s biologics manufacturing capacity in the US to meet the needs of the Company’s maturing pipeline...
11 September 2015 | By Victoria White
Interim results from the independent AMBER study demonstrated a 98% SVR12 rate in patients who completed a 12- or 24-week treatment regimen...
10 September 2015 | By Victoria White
The Indian domestic pharma market is estimated to reach US$ 15 billion by the end of the 2015 financial year, says India Brand Equity Foundation (IBEF)...
